Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China

Clinical Therapeutics

Volumn 33, Issue 10, 2011, Pages 1446-1455

  Wu, Bin ^a   Chen, Huafeng ^a   Shen, Jinfang ^a   Ye, Ming ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chemotherapy; Cost effectiveness; Non small cell lung cancer; Rh endostatin

Indexed keywords

CISPLATIN; DOCETAXEL; NAVELBINE; RECOMBINANT ENDOSTATIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINA; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDOSTATINS; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 80054900758     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.016     Document Type: Article

References (22)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. William W.N., Lin H.Y., Lee J.J., et al. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136:701-709.
3. Gridelli C., Ardizzoni A., Douillard J.Y., et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010, 68:319-331.
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
5. Wang J., Sun Y., Liu Y., et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients [in Chinese]. Zhongguo Fei Ai Za Zhi 2005, 8:283-290.
6. Sun Y., Wang J., Liu Y., et al. Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005, 23(Suppl). Abstract 7138.
7. Ling Y., Yang Y., Lu N., et al. Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 2007, 361:79-84.
8. Brennan A., Akehurst R. Modelling in health economic evaluation. What is its place? What is its value?. Pharmacoeconomics 2000, 17:445-459.
9. Barton P., Bryan S., Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004, 9:110-118.
10. Liu Q., Wang B., Kong Y., Cheng K.K. China's primary health-care reform. Lancet 2011, 377:2064-2066.
11. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372:1809-1818.
12. Carlson J.J., Garrison L.P., Ramsey S.D., Veenstra D.L. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009, 12:20-27.
13. Thompson S.G., Nixon R.M. How sensitive are cost-effectiveness analyses to choice of parametric distributions?. Medical Decision Making 2005, 25:416-423.
14. Doubilet P., Begg C.B., Weinstein M.C., et al. Probabilistic sensitivity analysis using Monte Carlo simulation. Medical Decision Making 1985, 5:157-177.
15. Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005, 8:1-2.
16. Eichler H.G., Kong S.X., Gerth W.C., et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?. Value Health 2004, 7:518-528.
17. Siebert U., Sroczynski G., Aidelsburger P., et al. Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Pharmacoeconomics 2009, 27:341-354.
18. Threshold Values for Intervention Cost-Effectiveness by Region WHO-CHOICE, Accessed October 15, 2010. http://www.who.int/choice/costs/CER_levels/en/index.html.
19. Joerger M., Matter-Walstra K., Fruh M., et al. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2011, 22:567-574.
20. Fojo T., Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048.
21. Sheldon T.A. Problems of using modelling in the economic evaluation of health care. Health Econ 1996, 5:1-11.
22. Shin H.R., Masuyer E., Ferlay J., Curado M.P. Cancer in Asia-Incidence rates based on data in cancer incidence in five continents IX (1998-2002). Asian Pac J Cancer Prev 2010, 11(Suppl 2):11-16.